PRISCILA MUNIZ GONCALVES DE MORAES

Índice h a partir de 2011
1
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas, Faculdade de Medicina - Médico

Filtros

Limpar filtros

Configurações

Resultados de Busca

Agora exibindo 1 - 3 de 3
  • conferenceObject
    Proton pump inhibitors and antibiotics impact on toxicities and clinical outcomes in cancer patients treated with immunotherapy.
    (2021) ARAUJO, Haniel Alves; MONIZ, Camila Motta Venchiarutti; BRAGHIROLI, Oddone Freitas Melro; MAK, Milena Perez; URATANI, Lucas Fernando; TIECHER, Ricardo Dahmer; MORAES, Priscila Muniz; BARBOSA, Ingrid; CAMARGO, Veridiana Pires De; BRAGHIROLI, Maria Ignez Freitas Melro; CASTRO, Gilberto; HOFF, Paulo Marcelo; DIZ, Maria Del Pilar
  • conferenceObject
    Definitive chemoradiotherapy for squamous cell carcinoma of the anal canal (SCCAC) with cisplatin and capecitabine: A prospective cohort-preliminary results.
    (2021) DORNELLAS, Abraao; MORAES, Priscila Muniz; VICTOR, Carolina Ribeiro; BONADIO, Renata Colombo; BRAGHIROLI, Maria Ignez; CHEN, Andre Tsin Chih; ORTEGA, Cinthia; NAHAS, Caio; HOFF, Paulo Marcelo; MOTTA, Camila; MONIZ, Venchiarutti
  • article 1 Citação(ões) na Scopus
    Real-world Data for High-risk Stage II Colorectal Cancer - The Role of Tumor Side in the Adjuvant Setting
    (2021) ARAUJO, Camila S.; MONIZ, Camila M. Venchiarutti; BONADIO, Renata C.; WATARAI, Gabriel Y.; ROJAS, Jessica; NOGUEIRA, Pedro V. S.; MARTINEZ, Jessica K.; MORAES, Priscila M. G.; I, Maria Braghiroli; SABBAGA, Jorge; HOFF, Paulo M.
    The impact of sidedness in the high-risk stage II colorectal cancer setting is uncertain. Although controversial, data suggest a modest benefit of adjuvant chemotherapy in this scenario. This study analyzes the overall survival and recurrence-free survival according to the tumor side and considers adjuvant chemotherapy exposure and clinical and molecular features. In this retrospective cohort, the tumor side did not influence overall survival. Background: The impact of sidedness in the high-risk stage II colorectal cancer (CRC) setting is uncertain. Although controversial, available data suggest a possible modest benefit of adjuvant chemotherapy (CT) in the adjuvant scenario. The aim of this study is to analyze the overall survival (OS) and recurrence-free survival (RFS) according to the tumor side. Patients and Methods: In this single-center retrospective cohort, we analyzed patients treated between January 2011 and December 2018. We evaluated OS and RFS of high-risk patients according to the tumor side and considering adjuvant CT exposure and clinical and molecular features. Results: A total of 1047 patients with stage II CRC were evaluated. Of these, 540 had high-risk criteria and microsatellite stability (MSS) or unknown status. One hundred fifty-seven (29%) patients had right-sided tumors, and 352 (65.2%) had left-sided tumors. Most patients received adjuvant CT, and the majority of them had T3 stage tumors, >= 12 lymph node resection, left tumor, MSS, and moderate differentiation. OS did not differ according to tumor side (5-year OS rates: 81.9% for right-sided tumors vs. 83% for left-sided tumors; hazard ratio, 0.91; 95% confidence interval, 0.55-1.53; P = .744). Adjuvant CT was associated with a superior RFS and OS, with 5-year OS rates of 87.7% versus 76.1% in the no-adjuvant group (hazard ratio, 0.46; 95% CI, 0.28-0.73; P = .001). Conclusion: The tumor side did not influence the outcomes in this study. Adjuvant CT was associated with improved RFS and OS in patients with high-risk stage II CRC, with a total gain of 11.6% in 5-year OS.